Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular diagnostics company specializing in early cancer detection, continues to gain recognition as a pioneering force in the field. With a strong performance in 2024 and expanding global partnerships, the company is making bold strides in transforming how cancer is diagnosed—starting with colorectal and pancreatic cancers.
Last year marked a series of strategic and scientific milestones for Mainz Biomed. Among them was achieving full compliance with all Nasdaq listing requirements—an important benchmark that not only strengthens investor confidence but also signals the company’s readiness for broader market activity.
The company’s momentum is being propelled by the eAArly DETECT 2 clinical trial, a follow-up to its earlier landmark study. This initiative is designed to improve the accuracy and accessibility of colorectal cancer screening, with preliminary results showing 97% sensitivity for colorectal cancer, 82% sensitivity for advanced precancerous lesions, and a 100% detection rate for high-grade dysplasia—outcomes that could significantly elevate diagnostic standards.
Mainz’s ColoAlert® test, a non-invasive, at-home colorectal screening solution, continues to gain traction in Europe. In 2024, revenue from Mainz’s lab partner network grew by 33% year-over-year, pointing to both rising demand and increasing physician adoption across the region.
Beyond colorectal cancer, the company is setting its sights on pancreatic cancer—one of the most difficult cancers to detect early. In partnership with Liquid Biosciences, Mainz is advancing a novel blood-based screening test that has demonstrated 95% sensitivity and 98% specificity in early studies. If further validated, it could offer a much-needed breakthrough in detecting this often fatal disease at a treatable stage.
The company has also secured two key collaborations to support its scientific and regulatory ambitions. A partnership with Thermo Fisher Scientific is focused on developing next-generation diagnostics for colorectal cancer, while Quest Diagnostics is supporting a major U.S.-based clinical study intended to pave the way for FDA approval of ColoAlert® in the American market.
“We believe we are entering a transformative era,” said Guido Baechler, CEO of Mainz Biomed. “Our technology has the potential to redefine early cancer detection and improve patient outcomes on a global scale.”
With its comprehensive biomarker approach, expanding market footprint, and innovative research pipeline, Mainz Biomed is positioning itself to play a key role in shaping the future of cancer diagnostics. As competition intensifies in the oncology space, Mainz’s blend of precision science and strategic collaboration gives it a distinct edge in both the European and U.S. arenas.
Follow the original source on mainzbiomed.com.
